Sylvie Rato

ORCID: 0000-0002-0204-0335
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • Immune Cell Function and Interaction
  • Hepatitis C virus research
  • Single-cell and spatial transcriptomics
  • CRISPR and Genetic Engineering
  • Cytomegalovirus and herpesvirus research
  • T-cell and B-cell Immunology
  • Biochemical and Molecular Research
  • HIV/AIDS Research and Interventions
  • interferon and immune responses
  • Bacteriophages and microbial interactions
  • Animal Disease Management and Epidemiology
  • Fungal Infections and Studies
  • Plant Pathogens and Fungal Diseases
  • Nail Diseases and Treatments
  • T-cell and Retrovirus Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Bioinformatics and Genomic Networks
  • Virology and Viral Diseases

University of Lausanne
2015-2019

Inserm
2013-2016

University of Lisbon
2006-2015

Université Paris Cité
2013

Délégation Paris 7
2013

Instituto de Medicina Molecular João Lobo Antunes
2012

Universidade Nova de Lisboa
2006

Despite effective treatment, HIV can persist in latent reservoirs, which represent a major obstacle toward eradication. Targeting and reactivating cells is challenging due to the heterogeneous nature of HIV-infected cells. Here, we used primary model latency single-cell RNA sequencing characterize transcriptional heterogeneity during reactivation. Our analysis identified programs leading successful reactivation expression.

10.1016/j.celrep.2018.03.102 article EN cc-by Cell Reports 2018-04-01

Cellular permissiveness to HIV infection is highly heterogeneous across individuals. Heterogeneity also found CD4+ T cells from the same individual, where only a fraction of gets infected. To explore basis permissiveness, we performed single-cell RNA-seq analysis non-infected high and low permissive Transcriptional heterogeneity translated in continuum cell states, driven by T-cell receptor-mediated activation was strongly linked permissiveness. Proteins expressed at surface displaying...

10.1371/journal.ppat.1006678 article EN cc-by PLoS Pathogens 2017-10-26
Irena Zurnic Sylvia Hütter Ute Lehmann Nicole Stanke Juliane Reh and 95 more Tobias Kern Fabian Lindel Gesche Gerresheim Martin V. Hamann Erik Müllers Paul Lesbats Peter Cherepanov Erik Serrao Alan Engelman Dirk Lindemann Claire da Silva Santos Kévin Tartour Andrea Cimarelli Rya Burdick Jianbo Chen Jaya Sastri Wei-Shau Hu Vinay K. Pathak Oliver T. Keppler Karine Pradeau Sylvia Eiler Nicolas Lévy Sarah Lennon Sarah Cianférani Stéphane Emiliani Marc Ruff Vincent Parissi Sylvie Rato Antonio Rausell Miguel Muñoz Amalio Telenti Angela Ciuffi Alexander Zhyvoloup Anat Melamed I.G. Anderson Delphine Planas Janos Kriston‐Vizi Robin Ketteler Chen- Hsuin Lee Andy Merritt Petronela Ancuța Charles R. M. Bangham Ariberto Fassati Anthony Rodari Benoît Van Driessche Mathilde Galais Nadège Delacourt Sylvain Fauquenoy Caroline Vanhulle Anna Kula Arsène Burny Olivier Rohr Carine Van Lint Thijs van Montfort Renee van der Sluis Dave Speijer Ben Berkhout Bo Meng Andrzej Rutkowski Neil Berry Lars Dölken Andrew Lever Thomas Schuster Benedikt Asbach Ralf Wagner Gross Christine Veit Wiesmann Martina Kalmer Thomas Wittenberg Jan Gettemans Andrea K. Thoma-Kreß Minghua Li Eric O. Freed Shan‐Lu Liu J.Y. Muller Jan Münch Xaver Sewald Pradeep D. Uchil Mark S. Ladinsky Jagadish Beloor Ruoxi Pi Christin Herrmann Nasim Motamedi Thomas T. Murooka Michael A. Brehm Dale L. Greiner Thorsten R. Mempel Pamela J. Björkman Priti Kumar Walther Mothes Simone Joas Erica H. Parrish Clement W. Gnanadurai Edina Lump Christina M. Stürzel

Oral presentations Session 1: Entry & uncoating O1 Host cell polo-like kinases (PLKs) promote early prototype foamy virus (PFV) replication Irena Zurnic, Sylvia Hütter, Ute Lehmann, Nicole Stanke, Juliane Reh, Tobias Kern, Fabian Lindel, Gesche Gerresheim, Martin Hamann, Erik Müllers, Paul Lesbats, Peter Cherepanov, Serrao, Alan Engelman, Dirk Lindemann O2 A novel entry/uncoating assay reveals the presence of at least two species viral capsids during synchronized HIV-1 infection Claire Da...

10.1186/s12977-016-0294-5 article EN cc-by Retrovirology 2016-09-01

Throughout the HIV-1 replication cycle, complex host-pathogen interactions take place in infected cell, leading to production of new virions. The virus modulates host cellular machinery order support its life while counteracting intracellular defense mechanisms. We investigated dynamic response infection by systematically measuring transcriptomic, proteomic, and phosphoproteomic expression changes uninfected SupT1 CD4+ T cells at five time points viral process. By means a Gaussian...

10.1038/s41598-018-36135-3 article EN cc-by Scientific Reports 2019-01-14

HIV-1 is a complex retrovirus that uses host machinery to promote its replication. Understanding cellular proteins involved in the multistep process of infection may result discovery more adapted and effective therapeutic targets. Kinases phosphatases are druggable class critically regulation signal pathways eukaryotic cells. Here, we focused on kinases essential for replication but dispensable cell viability. We performed an iterative screen Jurkat T-cells with short-hairpin-RNA (shRNA)...

10.1371/journal.pone.0009276 article EN cc-by PLoS ONE 2010-02-16

This report describes application of PCR fingerprinting to identify common species dermatophytes using the microsatellite primers M13, (GACA)4, and (GTG)5. The initial analysis rendered a specific DNA fragment for Microsporum audouinii, which was cloned sequenced. Based on sequencing data this fragment, forward (MA_1F) reverse (MA_1R) were designed verified by establish their reliability in diagnosis M. audouinii. These produced singular band 431 bp only strains isolates based global test...

10.1128/jcm.00759-06 article EN Journal of Clinical Microbiology 2006-12-01

HIV resistance to the integrase inhibitor raltegravir in treated patients is characterized by distinct pathways. We hypothesize that differences vivo dynamics of are due genetic context present at baseline.We studied four whose viruses evolved towards different The baseline sequences were inserted into a reference clone. Primary mutations then introduced and their impact on viral replication capacity (RC) was measured.Patients A B experienced emergence persistence mutation N155H under...

10.1093/jac/dku424 article EN Journal of Antimicrobial Chemotherapy 2014-10-21

Abstract Type-I interferons (IFNs) induce the expression of hundreds cellular genes, some which have direct antiviral activities. Although IFNs restrict different steps HIV replication cycle, their dominant effect remains unclear. We first quantified inhibition by IFN in tissue culture, using viruses with tropism and growth kinetics. By combining experimental mathematical analyses, we determined quantitative estimates for key parameters demonstrate that mainly inhibits de novo infection (33%...

10.1038/srep11761 article EN cc-by Scientific Reports 2015-06-29

The human immunodeficiency virus type 1 (HIV-1) integrase (IN) protein plays an important role during the early stages of retroviral life cycle and therefore is attractive target for therapeutic intervention. We immunized rabbits with HIV-1 IN developed a combinatorial single-chain variable fragment (scFv) library against IN. Five different scFv antibodies high binding activity specificity were identified. These scFvs recognize catalytic C-terminal domains block strand-transfer process....

10.1002/bab.1034 article EN Biotechnology and Applied Biochemistry 2012-09-01

Background Type-I interferons (IFN) inhibit HIV replication by inducing the expression of several cellular genes, some which have direct antiviral activity. Forcing to replicate in culture presence IFN is expected lead selection variants with decreased susceptibility. The characterization emerging viral may help identifying nature activities induced capable affecting replication.

10.1186/1742-4690-10-s1-p93 article EN cc-by Retrovirology 2013-09-01

Background HIV resistance to the integrase inhibitor raltegravir (RAL) in treated patients is characterized by three main distinct pathways, for which primary mutations are: N155H, Q148H/K/R, or Y143R/H/C. These genotypes may emerge sequentially, always carried viral genomes. The mechanism explaining sequential emergence and vivo dynamics along with escape from RAL treatment are poorly understood. We hypothesize that differences of RAL, must be a direct consequence phenotypic expression...

10.1186/1742-4690-10-s1-p56 article EN cc-by Retrovirology 2013-09-01
Coming Soon ...